Background: Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), is common in cancer patients and surgery is an important risk factor.
Objective: To describe the occurrence of VTE in cancer patients following major surgery and to determine the risk of VTE recurrence.
Methods: Using the administrative health claims (RAMQ) and hospital discharge (MED-ECHO) databases of the province of Québec, Canada, we constructed a cohort of all individuals with incident VTE between January 1, 1994 and December 31, 2004 diagnosed with cancer and who had major surgery in the 91days prior to the VTE. The timing of VTE after surgery was determined. Recurrent VTE was defined as re-hospitalization with a principal discharge diagnosis of VTE.
Results: Our cohort consisted of 2706 cancer patients with VTE following major surgery. The mean age was 65.9years (Standard Deviation 12.6) and 54% were female. The median duration of surgical hospitalization was 18days (range 1-735days). The median time to VTE following surgery was 15days (range 1-659days), and 34% of VTE events were diagnosed after hospital discharge. The 1-year cumulative rate of recurrence was 6.7% (95% CI 5.7, 7.9) and the 5-year cumulative rate was 12.6% (95% CI 10.7, 14.7). Increasing comorbidity (adjusted hazard ratio (HR) 2.49, 95% CI 1.58-3.95) and VTE diagnosed after hospital discharge (adjusted HR 1.48, 95% CI 1.09-2.01) were associated with recurrence.
Conclusions: A significant proportion of VTE episodes among surgical patients with cancer are diagnosed after discharge from hospital. This suggests that surgical patients with cancer are at risk for VTE beyond the immediate postoperative period.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.thromres.2012.10.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Characterization and Detection Strategy Exploration in Cryptogenic Hepatocellular Carcinoma: Insights From a Super-Aged Region in Japan.
Cancer Med
January 2025
Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Japan.
Background And Aim: In recent years, there has been a rise in cryptogenic hepatocellular carcinoma (c-HCC) cases in Japan, posing a detection challenge due to an unknown etiology. This study aims to enhance diagnostic strategies for c-HCC by analyzing its characteristics and exploring current opportunities for detection.
Methods: A retrospective study was conducted from April 2012 to March 2022, enrolling 372 newly diagnosed hepatocellular carcinoma (HCC) patients.
Circulating Tumor HPV-DNA in the Management of HPV-Positive Oropharyngeal Carcinoma: A Systematic Review.
Head Neck
January 2025
Department of Otolaryngology, University of California, Irvine, Chao Family Comprehensive Cancer Center, Orange, California, USA.
Purpose: Blood-borne, cell-free DNA has been proposed as a means of individualizing the management of human papillomavirus (HPV)-positive oropharyngeal carcinoma.
Methods And Materials: This study was designed based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement. A comprehensive literature search of peer-reviewed publications from January 2013 to January 2024 was undertaken to identify prospective studies pertaining to the use of circulating HPV-DNA for oropharyngeal carcinoma.
Pelvic Radiotherapy in Rectal Cancer Patients With Synchronous Potentially Treatable Liver Metastases.
Cancer Rep (Hoboken)
January 2025
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Background: The optimal management strategy for Stage IV rectal cancer with potentially treatable liver metastases remains controversial, particularly regarding the role of pelvic radiotherapy (RT).
Aims: We intend to investigate the impact of pelvic RT on oncological outcomes of rectal cancer with potentially treatable liver metastasis.
Methods And Results: This retrospective study included 83 patients diagnosed with rectal cancer and synchronous liver metastases from June 2012 to January 2022.
DNA hypomethylation-related expression of hsa-miR-184 contributes to invasive growth of gonadotroph neuroendocrine pituitary tumors.
J Neuroendocrinol
January 2025
Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Gonadotroph neuroendocrine pituitary tumors are among the most common intracranial neoplasms. A notable proportion of these tumors is characterized by invasive growth which hampers the treatment results and worsens prognoses of patients. Increased hsa-miR-184 expression was observed in invasive as compared to non-invasive gonadotroph tumors.
View Article and Find Full Text PDFNEDD4-Mediated GSNOR Degradation Aggravates Cardiac Hypertrophy and Dysfunction.
Circ Res
January 2025
Key Laboratory of Drug Targets and Translational Medicine for Cardio-cerebrovascular Diseases, Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Jiangsu, China (X.T., X.L., X.S., Y. Zhang, Y. Zu, Q.F., L.H., S.S., F.C., L.X., Y.J.).
Background: The decrease in S-nitrosoglutathione reductase (GSNOR) leads to an elevation of S-nitrosylation, thereby exacerbating the progression of cardiomyopathy in response to hemodynamic stress. However, the mechanisms under GSNOR decrease remain unclear. Here, we identify NEDD4 (neuronal precursor cell expressed developmentally downregulated 4) as a novel molecule that plays a crucial role in the pathogenesis of pressure overload-induced cardiac hypertrophy, by modulating GSNOR levels, thereby demonstrating significant therapeutic potential.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!